CVS Health (CVS) is back in focus after second quarter results topped revenue and profit expectations, full year earnings guidance was raised, and a revamped GLP 1 weight management program was announced.

At a share price of US$97.16, CVS Health has seen a 1-day share price return of 2.28% and a year-to-date share price return of 21.25%. The 1-year total shareholder return of 46.13% and 3-year total shareholder return of 63.07% point to gains that investors have received from both price moves and distributions. This comes even though the 30-day share price return is down 9.59%, which suggests recent momentum has cooled after a stronger run.

If this kind of move in CVS Health has you thinking about where else growth and disruption may show up in healthcare, it could be a good moment to scan 42 healthcare AI stocks

After a sharp rerating on stronger earnings and a refreshed GLP 1 push, CVS Health now sits close to US$100 and well above where it started the year. Does the current balance of risk and reward still lean toward buyers?

Most Popular Narrative: 15% Undervalued

The most followed narrative for CVS Health places fair value at $114.88 compared with the recent $97.16 share price. That gap reflects specific views on earnings power, margins and how integrated healthcare can support future cash flows under a 7.5% discount rate.

Integration of recent and ongoing acquisitions (such as Aetna, Oak Street, and Signify Health) and vertical alignment between insurance, pharmacy, and care delivery provide substantial cross-selling and synergy opportunities, supporting long-term operating margin and earnings growth as margin recovery initiatives gain traction.

Curious what sits behind that $114.88 figure? The narrative leans on specific paths for revenue, margin rebuild and future earnings multiples that are not immediately obvious from recent headlines.

Result: Fair Value of $114.88 (UNDERVALUED)

However, CVS Health still faces real swing factors, including persistent pharmacy reimbursement pressure and uncertainty around medical loss ratios in key insurance lines.

Next Steps

Seeing both optimism and caution around CVS Health in the data is a useful signal. Act quickly and review the underlying numbers yourself, starting with 3 key rewards and 2 important warning signs.

Looking for more ideas beyond CVS Health?

If you are serious about building a stronger portfolio, do not stop with CVS Health. Use the Simply Wall St screener to quickly surface focused stock ideas.

• Target resilient income by reviewing companies that show up in the 10 dividend fortresses and see which payouts look most consistent with their financial profile.
• Spot potential mispriced opportunities by scanning the screener containing 20 high quality undiscovered gems before they attract wider attention from the market.
• Strengthen your downside protection by focusing on companies that pass the 80 resilient stocks with low risk scores and assessing how they could balance your higher volatility holdings.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.